[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intrathecal-anesthesia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intrathecal-anesthesia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100588813","phase-4-assessing-the-time-course-of-dexmedetomidine-induced-analgesia-via-eeg-100588813",false,"NCT06946277","Assessing the Time-Course of Dexmedetomidine-Induced Analgesia Via EEG","Mapping the Temporal Profile of Dexmedetomidine-Induced Analgesia Via EEG Signatures in Brain","Inclusion Criteria:\n\nPatients with hip osteoarthritis scheduled for total hip arthroplasty under intrathecal anesthesia; Age 18-70 years; American Society of Anesthesiologists (ASA) physical status classification I-III; Body mass index (BMI) 22-30 kg\u002Fm².\n\nExclusion Criteria:\n\nPre-existing peripheral or central nervous system disorders; Mental disorders; Cognitive impairment; Emergency surgery; or Hearing impairment.","ALL","18 Years","70 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Objective: To investigate the temporal dynamics of dexmedetomidine's analgesic effects in the brain using EEG.\n\nMethods: Eligible patients scheduled for total hip arthroplasty under intrathecal anesthesia received a continuous infusion of DEX at 1.5 μg\u002F(kg·h) for 15 minutes before neuraxial puncture, followed by an additional 15-minute infusion. The study was divided into three phases:\n\nPhase 1: Non-dosing phase (Baseline). Phase 2: DEX preemptive analgesia phase (DEX infusion). Phase 3: DEX cessation phase (Post-infusion).\n\nOutcomes:\n\nPrimary safety outcome: EEG spectral analysis at different phases. Secondary outcomes: NRS scores, postoperative nausea and vomiting (PONV), dizziness, agitation, and time to intestinal exhaust within 48 hours. Intraoperative hemodynamics were also monitored.",[27,28,29],"Total Hip Arthroplasty (THA)","Intrathecal Anesthesia","Hip Osteoarthritis","NOT_YET_RECRUITING","2025-04-23",{"date":33,"type":34},"2025-04-27","ACTUAL",{"date":36,"type":21},"2025-04-25",{"date":38,"type":21},"2025-05-26",{"name":40,"class":41},"China International Neuroscience Institution","OTHER"]